Legacy Capital Wealth Partners LLC Invests $42,000 in Exact Sciences Corporation $EXAS

Legacy Capital Wealth Partners LLC purchased a new stake in Exact Sciences Corporation (NASDAQ:EXAS) in the 4th quarter, HoldingsChannel.com reports. The firm purchased 41,837 shares of the medical research company’s stock, valued at approximately $42,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Centaurus Financial Inc. boosted its position in shares of Exact Sciences by 5.0% in the 3rd quarter. Centaurus Financial Inc. now owns 2,517 shares of the medical research company’s stock worth $138,000 after purchasing an additional 120 shares in the last quarter. Brookstone Capital Management increased its position in Exact Sciences by 1.5% during the 4th quarter. Brookstone Capital Management now owns 10,248 shares of the medical research company’s stock valued at $1,041,000 after buying an additional 148 shares in the last quarter. CoreCap Advisors LLC raised its stake in Exact Sciences by 16.1% during the fourth quarter. CoreCap Advisors LLC now owns 1,086 shares of the medical research company’s stock valued at $110,000 after buying an additional 151 shares during the last quarter. Comerica Bank raised its stake in Exact Sciences by 9.2% during the third quarter. Comerica Bank now owns 1,954 shares of the medical research company’s stock valued at $107,000 after buying an additional 164 shares during the last quarter. Finally, Great Lakes Advisors LLC boosted its holdings in Exact Sciences by 3.7% in the first quarter. Great Lakes Advisors LLC now owns 4,971 shares of the medical research company’s stock worth $215,000 after acquiring an additional 178 shares in the last quarter. 88.82% of the stock is currently owned by institutional investors.

Exact Sciences Stock Performance

Shares of NASDAQ:EXAS opened at $104.91 on Friday. The stock has a market capitalization of $20.03 billion, a price-to-earnings ratio of -95.37, a PEG ratio of 2.02 and a beta of 1.41. The company has a debt-to-equity ratio of 0.97, a quick ratio of 2.17 and a current ratio of 2.43. The stock’s 50-day simple moving average is $103.57 and its two-hundred day simple moving average is $89.19. Exact Sciences Corporation has a 52-week low of $38.81 and a 52-week high of $104.98.

Exact Sciences (NASDAQ:EXAS) last released its quarterly earnings results on Friday, February 13th. The medical research company reported ($0.21) EPS for the quarter, missing the consensus estimate of $0.08 by ($0.29). Exact Sciences had a negative net margin of 6.40% and a positive return on equity of 0.53%. The business had revenue of $878.38 million for the quarter, compared to analysts’ expectations of $860.59 million. During the same period in the previous year, the company earned ($0.06) EPS. Exact Sciences’s revenue for the quarter was up 23.1% compared to the same quarter last year. Analysts expect that Exact Sciences Corporation will post -0.58 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Evercore set a $105.00 price target on Exact Sciences and gave the company an “in-line” rating in a report on Monday, January 5th. Zacks Research downgraded shares of Exact Sciences from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Exact Sciences in a research note on Thursday, January 22nd. BTIG Research reaffirmed a “neutral” rating on shares of Exact Sciences in a report on Tuesday, March 24th. Finally, Mizuho reiterated a “neutral” rating and issued a $105.00 target price (up from $85.00) on shares of Exact Sciences in a research note on Tuesday, January 20th. Twenty-one analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Reduce” and an average target price of $92.13.

About Exact Sciences

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.